Tergus Pharma Announces New Commercial Manufacturing Facility and Partnership with Great Point Partners
Tergus Is Poised for Growth & Expansion by Adding Commercial Capabilities And Expanding Current Capacity
RESEARCH TRIANGLE PARK, N.C. and DURHAM, N.C., June 06, 2019 (GLOBE NEWSWIRE) — Tergus Pharma (“Tergus”), an end-to-end service provider for topical pharmaceutical research, drug development, testing and manufacturing, today has announced a 100,000-square-foot building for its new headquarters and plans to invest to expand into commercial manufacturing. Tergus will provide comprehensive services from development through manufacturing and will become a Contract Development and Manufacturing Organization, or CDMO.
Tergus announced a partnership with Great Point Partners (“GPP”) a Greenwich, CT based health care investment firm. GPP has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies.
Tergus provides Topical Formulation development, In Vitro Permeating Testing (IVPT), In Vitro Release Testing (IVRT), Skin Biology, Analytical services, and Clinical Trial Materials (CTM) manufacturing services for branded and generic dermatology products. Great Point’s investment will allow Tergus to build a state-of-the-art commercial manufacturing facility in the Raleigh-Durham, NC area and will begin construction in July 2019. The new 100,000 square foot facility will have Clinical Trial Material (Phases I thru III) Supplies and commercial manufacturing capabilities and expand current capacity by over 400%. Tergus plans to open the new facility in early 2020.
“Great Point’s expertise and successful track record growing pharmaceutical services companies was evident when they proactively approached us about a partnership. For years we have discussed building a commercial facility. The equity capital from GPP will enable us to do this and we will be able to better serve our customers by offering end-toend services including commercial manufacturing,” said Vijendra Nalamothu, Ph.D., CEO of Tergus. “Great Point’s experience, network, and success in current and previous outsourced pharmaceutical services investments was a true differentiator.”
“Tergus has differentiated itself as a leader in the complex topical dermatology development space that has been growing at ~15% per year,” said Rohan Saikia, Managing Director at Great Point Partners. “Tergus’ reputation within topical dermatology is unparalleled and we are thrilled that Tergus will now be a ‘one-stop-shop’ from clinical development to commercial manufacturing for all of their clients.”
About Tergus Pharma
Tergus, an end-to-end service provider for topical pharmaceutical research, drug development, testing and manufacturing company, has been an industry leader for several years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality results to clients from formulation through clinical supplies manufacturing, which is why people say, “Think Topicals, Think Tergus.” A systematic and scientific approach is used to thoroughly understand product components, processing, and finished product attributes to ensure high quality product throughout the course of development. Tergus helps its client achieve a balance between a fast-tracked program and quality science. For more information, please visit https://www.TergusPharma.com/
About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.6 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has committed capital of $286 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.1 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, hospital outsourcing and alternate site care, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203- 971-3300 or www.gppfunds.com.
Tergus Pharma, LLC
2810 Meridian Parkway, Ste 120
Durham, NC 27713
Tel +1 (919) 549-9702
- Tergus Pharma Announces New Commercial Manufacturing Facility and Partnership with Great Point Partners
- Skin Cancer Drug Fast-tracked to Patients in UK
- BioPharma Reporter Analysis of Biosimilars
- Recent Studies on Oxytocin as a Therapy for Autism
- Tergus at the 6th AGAH Dermatology Product Development Workshop
- The View from the Floor of the World Congress of Dermatology Conference